Sight Sciences launches pivotal trial of TearCare dry-eye disease treatment

Ophthalmic medical device company Sight Sciences today announced the launch of a new pivotal trial exploring the safety and effectiveness of its TearCare system in patients with dry eye disease. The Menlo Park, Calif.-based company’s TearCare system is a wearable therapeutic eyelid technology designed to deliver energy over a specified period to liquify meibum, an oily coating on the eye’s surface which prevents tear film evaporation. The device allows the patient to blink and for the eye to remain comfortably open during the procedure, Sight Sciences said. “We need additional treatment options for dry eye. I like several aspects of the TearCare System’s iLid device. It is non-invasive and conforms to the patient’s lid anatomy thereby individualizing and optimizing treatment and allows the patient to blink freely throughout the procedure,” Dr. Edward Holland of the Cincinnati Eye Institute said in a prepared statement. The randomized, controlled, 200-patient Olympia trial aims to explore the safety and effectiveness of the system in treating signs and symptoms of dry eye disease compared to a daily regimen of warm compress therapy and lid massage, the company said. “I am excited to participate in the Olympia trial and offer a customized, non-invasive treatment option to my patients. Unlike other dry eye technologies, the TearCare System is a smart and wearable solution that automatically regulates and maintains sufficiently eleva...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Optical/Ophthalmic Sight Sciences Source Type: news